Chairman of the Board
Michael Rapp has more than 25 years of experience in the financial industry and is the Managing Member of Broadband Capital Investments, LLC, a middle-market private equity sponsor focused on high growth companies. Mr Rapp has been instrumental in providing early financing and for advising exciting growth companies including; Examworks (acquired by Leonard Green), Montrose Environmental (the leading US environmental services company), Vroom.com(the leading internet used car company), Zynerba Pharmaceuticals (NASDAQ:Zyne) , a leading cannabinoid biotech company, and Hydrofarm (a leading hydroponics distribution company). Mr. Rapp received his BA degree in psychology from the University of Michigan-Ann Arbor in 1989.
John LaMattina, PhD
Dr. LaMattina is an Independent Non-Executive Director at PureTech Health and was previously President of Pfizer Global Research and Development and Senior Vice President of Pfizer, Inc. During his 30 year career at Pfizer Inc., Dr. LaMattina held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999. In 2010 he was the recipient of the American Chemical Society’s Earle B. Barnes Award for Leadership in Chemical Research Management. Dr. LaMattina received a B.S. in Chemistry from Boston College in 1971, and received a Ph.D. in Organic Chemistry from the University of New Hampshire in 1975. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor. Dr. LaMattina serves on the Board of Directors of PureTech Health, Ziarco Pharmaceuticals, Ligand Pharmaceuticals, Vedanta Biosciences, is Chairman of the Board of Gelesis, and is a member of the Scientific Advisory Board of Trevena pharmaceuticals. He is the author of Devalued and Distrusted – Can the pharmaceutical industry restore its broken image? and is the author of the Drug Truths blog at Forbes.com.
Michael Lefenfeld is co-founder and chief executive officer of New York City-based SiGNa Chemistry, a global manufacturer of highly-active, environmentally friendly chemicals. SiGNa’s products are used to improve production processes in the energy recovery, petrochemical refining and chemical manufacturing industries. His work has led to safer industrial environments, better medical technologies and more effective, affordable energy solutions. Prior to SiGNa, Lefenfeld developed and commercialized several new technologies, launching and selling three companies by age 30. Lefenfeld holds more than 50 patents in medical devices, controlled release, electronics, chemical reactivity and information technology. After earning a bachelor’s degree in chemical engineering at WashU in 2002, Lefenfeld, a resident of New York City, earned a master’s in chemistry at Columbia University and an executive education certificate at Stanford University’s Graduate School of Business.
Michael J. Morin, PhD
Mike Morin, PhD, serves as Immunome’s Chief Scientific Officer. He has had a productive career in cancer research, with a long-standing commitment to improving patient care. As Vice President in Pfizer Global R&D, he led Antibacterials, Immunology and Cancer drug discovery in Groton, CT. During his extensive Pfizer career, Mike had oversight for the discovery of approximately 40 clinical candidates, many of which are progressing in active development. Most notable among those activities was his direct leadership in the discovery through Phase 2 proof-of-concept for erlotinib (TarcevaTM), a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase (a blockbuster drug marketed by Roche and Astellas). Additional candidates from his teams, both monoclonal antibodies and small molecules, have also achieved full development status and are moving through late-stage clinical trials and NDA filings. Since 2008, Mike worked as an advisor and as a C-level interim leader of venture-backed biotechnology companies, including Supportive Therapeutics (CEO) and Onkaido (CSO). Mike remains a committed supporter of academic cancer programs at the local and national levels, and he continues to contribute to the peer-review process within the cancer research community. This includes many years of service as co-chair of the NCI Experimental Therapeutics (NExT) review panel, chair of the Drug Discovery Initiative of the Children’s Tumor Foundation, and the Scientific Advisory Boards of the Ontario Institute of Cancer Research and of the Terri Brodeur Breast Cancer Foundation. Mike also serves as an executive advisor for the sciences and new ventures at UMass Lowell, where he is also an adjunct professor in the Kennedy College of Sciences. Mike received his baccalaureate in Biological Sciences from UMass Lowell and his PhD in Cancer Pharmacology from SUNY Buffalo (Roswell Park Graduate Division). He was an NIH postdoctoral fellow with Professor Alan Sartorelli at the Yale Comprehensive Cancer Center.
Wistar Morris, III
Wistar Morris, III is Senior Investment Consultant to Pennsylvania Trust. In April 2011, he retired from Boenning & Scattergood, an Investment Securities firm, where he served as a Director and Investment Advisor for 20 years. Previously, Mr. Morris founded the Morris Investment Management Company and held the roles of President and Chairman. Mr. Morris was also Executive Vice President with the investment management firm Hopper Soliday & Co. Mr. Morris has been on the boards of 20 public and private companies. In the non-profit world, he currently serves as emeritus trustee to The Academy of Natural Science, Lankenau Medical Center, Lankenau Institute of Medical Research and the Mount Desert Island Biological Laboratory. He is the Founder and CEO of The Cotswold Foundation and is the author of Adventures in Investing which describes his career in the investment business. Mr. Morris received a BS degree in Chemistry from Cornell University, an MBA from the Harvard Business School, and holds the CFA designation from the CFA Institute.
Purnanand Sarma, PhD
Dr. Purnanand Sarma serves as the President and Chief Executive Officer of Immunome. Sarma brings more than 25 years of experience in all aspects of pharmaceutical industry business across multiple R&D platforms, ranging from venture-backed biotechnology start-ups to large cap pharmaceutical companies. He was most recently the President & CEO of Taris Biomedical, which he built over the last nine years into a leader in therapeutic urology, focused on diseases such as bladder cancer and overactive bladder. In addition to raising more than $100M in equity capital, he also sold one of Taris’ products to Allergan (NYSE:AGN) in a deal worth up to $587M. Prior to Taris, Sarma was the VP and General Manager of World-wide Drug Delivery Technologies for Cephalon Corporation (NYSE:CEPH). Before joining Cephalon, he spent over 10 years in various capacities at Nektar Therapeutics (NASDAQ:NKTR), including VP of Drug Development & Program Management and built the entire green field operation of Nektar Therapeutics (India), serving as its first Managing Director. He started his career at SmithKline Beecham in King of Prussia, PA, after earning his PhD in Pharmaceutics from the University of Minnesota and B. Pharm from Andhra University, Visakhapatnam, India. Sarma also serves as an independent Board member at Ohm Oncology and Vaxess Technologies Inc.
Mr. Wagenheim has more than 25 years of experience in the financial industry and is the Managing Partner of Broadband Capital Partners, LLC, a middle-market private equity sponsor focused on growth companies and industry consolidations. Prior to Broadband Capital Partners, he was the vice-chairman of Broadband Capital Management LLC, an investment and merchant bank he co-founded in 2000. Mr. Wagenheim has extensive experience with public and private growth equity investments, including Zynerba Pharmaceuticals (Nasdaq: ZYNE), ExamWorks (Nasdaq: EXAM), vroom.com and Montrose Environmental Group. In connection with Zynerba’s recapitalization, Mr. Wagenheim was named President and a Director of the company, serving as a director until the company’s initial public offering in August 2015 led by Jefferies and Piper Jaffray. Mr. Wagenheim also serves as a director of Committed Capital Acquisition Corporation II (OTCQB: CCAQ). Mr. Wagenheim received his degree in Business Administration from the University of Miami.
Michael Widlitz, MD
Dr. Michael Widlitz, MD, has more than 30 years of experience in the health care industry including clinical practice and 20-plus years in the pharmaceutical industry with expertise in clinical development and medical affairs. He currently serves as a consultant to the pharmaceutical, biotechnology, and medical device industries. Prior to his consulting activities, Dr. Widlitz served as Vice President, US Medical for the Specialty Markets at Pfizer, leading the medical teams responsible for the Oncology, HIV/Anti-infective, Ophthalmology, Endocrine Care and Diversified Product Portfolios. His areas of responsibility included strategy development (clinical development through commercial products); clinical trial management; clinical data interpretations; and medical communications relative to key products, such as Sutent®, Macugen® & Eraxis™. Previously at Pfizer, Dr. Widlitz served as Vice President and Group Leader in Urology, Respiratory, Arthritis and Women’s Health franchises supporting key global product launches and leading Medical Affairs for products including Viagra®, Celebrex® and Zyrtec®. He also led the medical teams that provided support to Pfizer’s New Product Development Group. Dr. Widlitz serves on the Melanoma Advisory Board at the Wistar Institute and as a Business Advisor/Selection Team member to the University City Science Center QED Program. He is also an active life science angel investor through the Mid-Atlantic Angel Group, leading many of its Life Science sector due diligence activities. Dr. Widlitz earned a BA degree with distinction from the University of Michigan. He received his MD from George Washington University School of Medicine and completed a residency in otolaryngology at Albert Einstein College of Medicine. He is Board Certified by the American Board of Otolaryngology and Head and Neck Surgery.